EUVIMEDTutustu EUVIMEDiin
Open access · CC BY 4.0

Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer

Hakan Özçelik iD, Nazan Demir iD, Melisa Eryaşar iD, Oğuz Çelebi iD, Erdem Sünger iD, Burçin Çakan Demirel iD, Jamshid Hamdard iD, Özgür Açıkgöz iD, Burak Giray iD, Doğan Vatansever, İsa Aykut Özdemir, Volkan Ülker and 3 more

Journal of Clinical Medicine · 2026-08-16 · 15 (16) · 6326

DOI: 10.3390/jcm15166326 ↗

At a glance

Journal article in Journal of Clinical Medicine, published online on 2026-08-16. Written by Hakan Özçelik and 14 co-authors. Institution: Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey. Cited 1 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY 4.0).

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Background/Objectives: The 2023 revision of the International Federation of Gynecology and Obstetrics (FIGO) staging system redefines endometrial cancer staging by integrating histopathological and molecular parameters into conventional anatomic assessment. We aimed to quantify stage migration following reclassification from FIGO 2009 to FIGO 2023, to evaluate its impact on survival, and to identify independent prognostic determinants within this restaged cohort.

Methods

In this two-center retrospective cohort study, 291 patients with histologically confirmed endometrial cancer were restaged according to both FIGO 2009 and FIGO 2023 systems. Progression-free survival (PFS) and overall survival (OS) were assessed using the Kaplan–Meier method, and independent prognostic determinants were identified through multivariable Cox proportional hazards modeling.

Results

Application of FIGO 2023 resulted in stage migration in 32.0% of patients, with 30.6% upstaged and 1.4% downstaged. Upstaged patients demonstrated significantly worse PFS and OS compared with downstaged patients and patients without stage change (p < 0.001 for both). Notably, among patients initially classified as FIGO 2009 stage I, 38% were reassigned to a higher stage and exhibited a marked survival disadvantage (p < 0.001). In multivariable analysis, advanced age and positive surgical margins independently predicted both poorer PFS and OS, while lymphovascular space invasion (LVSI) independently predicted inferior PFS. The association with positive surgical margins, however, likely reflected concurrent advanced-stage disease.

Conclusions

The FIGO 2023 staging system results in substantial stage redistribution in endometrial cancer and provides clearer survival discrimination, particularly by identifying previously unrecognized high-risk subgroups within early-stage disease. The significant survival disadvantage observed among upstaged patients indicates that the revised system may more accurately reflect biologically driven risk stratification. However, stage migration was not independently associated with survival after adjustment for its constituent pathological factors.

Subjects

Author keywords

FIGO 2023endometrial cancerlymphovascular space invasionmolecular classificationoverall survivalprognosisprogression-free survivalrisk stratificationstage migrationsurgical margin

Authors and institutions

  • Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey.
  • Department of Medical Oncology, Koc University Hospital, Istanbul 34010, Turkey.
  • Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey.
  • Department of Internal Medicine, Koc University Hospital, Istanbul 34010, Turkey.
  • Department of Gynecologic Oncology, Koc University Hospital, Istanbul 34010, Turkey.
  • Department of Gynecologic Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey.

ORCID profiles: Hakan Özçelik, Nazan Demir, Melisa Eryaşar, Oğuz Çelebi, Erdem Sünger, Burçin Çakan Demirel, Jamshid Hamdard, Özgür Açıkgöz, Burak Giray, Çağatay Taşkıran, Ahmet Bilici

Cite

APA

Özçelik, H., Demir, N., Eryaşar, M., Çelebi, O., Sünger, E., Çakan Demirel, B., Hamdard, J., Açıkgöz, Ö., Giray, B., Vatansever, D., Özdemir, İ. A., Ülker, V., Taşkıran, Ç., Selcukbiricik, F., & Bilici, A. (2026). Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer. Journal of Clinical Medicine, 15(16), 6326. https://doi.org/10.3390/jcm15166326

Vancouver

Özçelik H, Demir N, Eryaşar M, Çelebi O, Sünger E, Çakan Demirel B, et al. Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer. Journal of Clinical Medicine. 2026;15(16):6326. doi:10.3390/jcm15166326

BibTeX
@article{zelik2026,
  author = {Özçelik, Hakan and Demir, Nazan and Eryaşar, Melisa and Çelebi, Oğuz and Sünger, Erdem and Çakan Demirel, Burçin and Hamdard, Jamshid and Açıkgöz, Özgür and Giray, Burak and Vatansever, Doğan and Özdemir, İsa Aykut and Ülker, Volkan and Taşkıran, Çağatay and Selcukbiricik, Fatih and Bilici, Ahmet},
  title = {Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {16},
  pages = {6326},
  doi = {10.3390/jcm15166326}
}
Start for free →